E/C/F/TAF

DRUG19 trials

Conditions

Acquired Immune Deficiency Syndrome (AIDS)Acquired Immunodeficiency SyndromeHBVHCV InfectionHIVHIV InfectionsHIV-1HIV-1 Infection

Phase 1

Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication

CompletedNCT03092206

Technical University of MunichInsulin Resistance

Start: 2017-04-18End: 2017-07-28Updated: 2017-08-21

Phase 2

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01497899

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2011-12-28End: 2016-08-22Updated: 2018-11-19

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

CompletedNCT01854775

Gilead SciencesAcquired Immune Deficiency Syndrome (AIDS), HIV Infections

Start: 2013-05-06End: 2025-06-18Updated: 2026-01-09

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

CompletedNCT02276612

Gilead SciencesHIV

Start: 2014-12-03End: 2017-10-23Updated: 2018-11-19

Phase 3

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

CompletedNCT01705574

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2012-10-24End: 2018-09-06Updated: 2019-09-20

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

CompletedNCT01780506

Gilead SciencesHIV, HIV Infections

Start: 2012-12-26End: 2017-09-06Updated: 2018-11-19

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

CompletedNCT01797445

Gilead SciencesHIV, HIV Infections

Start: 2013-03-12End: 2018-10-03Updated: 2020-03-02

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

CompletedNCT01815736

Gilead SciencesHIV, HIV Infections

Start: 2013-03-27End: 2020-04-01Updated: 2021-04-13

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

CompletedNCT01818596

Gilead SciencesHIV, HIV Infections

Start: 2013-03-27End: 2018-07-18Updated: 2020-03-02

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

CompletedNCT01967940

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV, HIV Infections

Start: 2013-10-25End: 2017-07-31Updated: 2018-11-16

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

CompletedNCT01968551

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV-1, HIV Infections

Start: 2013-09-03End: 2016-07-09Updated: 2018-11-16

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

CompletedNCT02071082

Gilead SciencesHBV, HIV

Start: 2014-02-25End: 2016-10-26Updated: 2018-11-16

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

CompletedNCT02600819

Gilead SciencesHIV-1 Infection

Start: 2015-12-14End: 2019-10-15Updated: 2020-11-05

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

CompletedNCT02605954

Gilead SciencesHIV-1 Infection

Start: 2015-11-18End: 2018-01-24Updated: 2018-11-14

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

CompletedNCT02616029

Gilead SciencesHIV-1 Infection

Start: 2015-12-17End: 2019-07-11Updated: 2020-07-23

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

CompletedNCT02616783

Gilead SciencesHIV-1 Infection

Start: 2015-12-22End: 2018-03-21Updated: 2020-03-04

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

CompletedNCT02652624

Gilead SciencesHIV-1 Infection

Start: 2016-02-19End: 2018-11-26Updated: 2020-03-04

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

CompletedNCT02707601

Gilead SciencesHCV Infection, HIV-1 Infection

Start: 2016-04-01End: 2017-09-29Updated: 2018-11-14

Phase 4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

RecruitingNCT06337032

Gilead SciencesHIV-1-infection

Start: 2024-08-27End: 2034-03-01Target: 350Updated: 2026-03-16

Journal of the Pediatric Infectious Diseases Society2025-07-01

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg

Journal of the International AIDS Society2025-01-30

Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis

UNC Libraries2024-10-17

Bictegravir/emtricitabine/tenofovir alafenamide in adults with <scp>HIV</scp>‐1 and end‐stage kidney disease on chronic haemodialysis

HIV Medicine2024-10-062 citations

Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials

HIV Medicine2022-08-178 citations

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with <scp>HIV</scp>: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

HIV Medicine2022-05-0838 citations

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.

2021-03-0939 citations

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation

JAIDS Journal of Acquired Immune Deficiency Syndromes2020-12-107 citations

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Carolina Digital Repository (University of North Carolina at Chapel Hill)2020-04-22

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.

2020-01-293 citations

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

JAIDS Journal of Acquired Immune Deficiency Syndromes2019-10-1454 citations

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

2019-10-0136 citations

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

2018-12-1323 citations

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment

AIDS Research and Human Retroviruses2018-01-2588 citations

Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.

2017-06-2924 citations

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

2017-03-0257 citations

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

2016-10-1733 citations

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

2016-05-2768 citations

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

2016-04-01127 citations

2015-11-02223 citations

1 more papers not shown

E/C/F/TAF

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Phase 4

Related Papers